AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina
- AXT107 exhibited a dual mechanism of action as a monotherapy, disrupting a key component of the Vascular Endothelial Growth Factor (VEGF) signaling pathway while also activating the Tie2 pathway that is integral to maintenance of vascular homeostasis.
- A single monotherapy injection of AXT107 demonstrated in vivo efficacy lasting for many months, suggesting patients may require only 1 to 2 injections per year.
- To date, AXT107 has demonstrated excellent safety, superior efficacy and longer durability in in vivo models compared to current standard of care treatments.
March 18, 2019